Twain Therapeutics is a pioneering biotechnology company developing precision gamma-chain cytokine therapies for cancer and autoimmunity.
The core technology is based on antibody-based agonists and antagonists. This approach increases the half-life of the therapeutic, which ultimately increases the therapeutic index and reduces the likelihood of side effects. Our molecules are targeted to amplify specific leukocyte responses, whilst minimising toxicity cause by off-target events.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Blk 531, Upper Cross Street, Hong Lim Complex, #03-62,singapore
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://twaintherapeutics.com/
- HQ
- Singapore, Singapore
Twain Therapeutics Questions
Twain Therapeutics's website is https://twaintherapeutics.com/
Twain Therapeutics's LinkedIn profile is https://sg.linkedin.com/company/twain-therapeutics
Twain Therapeutics has
6 employees.
View email and phone details for 6
employees at Twain Therapeutics.
Twain Therapeutics's industry is
Biotechnology Research
Twain Therapeutics's top competitors are
Msd,
Immunoscape,
Mirxes,
Albatroz Therapeutics,
Outram Bio,
Zeno Therapeutics Pte. Ltd.,
Tikva Allocell Pte Ltd,
Cytomed Therapeutics Limited,
Pairx Bio,
Hummingbird Bioscience.
Twain Therapeutics's categories are Biotechnology Research
Twain Therapeutics's founding year is 2020
